首页> 外文期刊>Urology >Male urethral carcinoma: analysis of treatment outcome.
【24h】

Male urethral carcinoma: analysis of treatment outcome.

机译:男性尿道癌:治疗结果分析。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: To evaluate our experience with primary carcinomas of the male urethra and to analyze the impact of tumor variables and treatment on overall, disease-specific, local recurrence-free, and metastasis-free survival. METHODS: Between 1958 and 1996, we identified 46 men with primary carcinoma of the bulbar and anterior urethra. The median follow-up was 125 months (1 to 336). The patients were stratified by stage, nodal status, histologic type, treatment, type of surgery, site of disease, year at diagnosis, and smoking status. RESULTS: The overall survival and disease-specific survival rates at 5 years were 42% and 50%, respectively. The recurrence-free survival and metastasis-free survival rates at 5 years were 51% and 56%, respectively. The overall survival rate was 83% for superficial disease versus 36% for invasive tumors. The overall survival rate was 26% for tumors of the bulbar urethra versus 69% for tumors of the anterior urethra. CONCLUSIONS: Current modalities of treatment are ineffective for local control and survival. New treatment strategies are needed for urethral cancer.
机译:目的:评估我们在男性尿道原发癌中的经验,并分析肿瘤变量和治疗对总体,疾病特异性,局部无复发和无转移生存的影响。方法:在1958年至1996年之间,我们确定了46名患有原发性延髓和前尿道癌的男性。中位随访时间为125个月(1至336个月)。按阶段,淋巴结状态,组织学类型,治疗,手术类型,疾病部位,诊断年限和吸烟状况对患者进行分层。结果:5年的总生存率和疾病特异性生存率分别为42%和50%。 5年的无复发生存率和无转移生存率分别为51%和56%。浅表疾病的总生存率为83%,而浸润性肿瘤的总生存率为36%。延髓尿道肿瘤的总生存率为26%,而前尿道肿瘤为69%。结论:目前的治疗方式对于局部控制和生存无效。尿道癌需要新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号